Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review

被引：1

作者：

Bongiovanni, Gabriele ^{[1
]}

Tonutti, Antonio ^{[1
]}

Stainer, Anna ^{[1
,2
]}

Nigro, Mattia ^{[1
]}

Kellogg III, Dean L. ^{[3
,4
]}

Nambiar, Anoop ^{[3
,4
]}

Gramegna, Andrea ^{[5
,6
,7
]}

Mantero, Marco ^{[5
,6
,7
]}

Voza, Antonio ^{[8
]}

Blasi, Francesco ^{[5
,6
,7
]}

Aliberti, Stefano ^{[1
,2
]}

Amati, Francesco ^{[1
,2
]}

机构：

[1] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Pieve Emanuele, Milan, Italy

[2] IRCCS Humanitas Res Hosp, Resp Unit, Via Manzoni 56, I-20089 Rozzano, Milan, Italy

[3] Univ Texas Hlth San Antonio, Dept Med, Div Pulm & Crit Care, San Antonio, TX USA

[4] South Texas Vet Hlth Care Syst, San Antonio, TX USA

[5] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[6] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Resp Unit, Milan, Italy

[7] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Cyst Fibrosis Adult Ctr, Milan, Italy

[8] IRCCS Humanitas Res Hosp, Emergency Med Unit, Via Manzoni 56, I-20089 Milan, Italy

来源：

BMJ OPEN RESPIRATORY RESEARCH | 2024年 / 11卷 / 01期

关键词：

Interstitial Fibrosis; Primary Pulmonary Hypertension; DOUBLE-BLIND; ARTERIAL-HYPERTENSION; INHALED TREPROSTINIL; FIBROSIS; SCLEROSIS; SAFETY; MULTICENTER; SILDENAFIL; DIAGNOSIS; RIOCIGUAT;

D O I：

10.1136/bmjresp-2023-002161

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Objectives Vasoactive drugs have exhibited clinical efficacy in addressing pulmonary arterial hypertension, manifesting a significant reduction in morbidity and mortality. Pulmonary hypertension may complicate advanced interstitial lung disease (PH-ILD) and is associated with high rates of disability, hospitalisation due to cardiac and respiratory illnesses, and mortality. Prior management hinged on treating the underlying lung disease and comorbidities. However, the INCREASE trial of inhaled treprostinil in PH-ILD has demonstrated that PH-ILD can be effectively treated with vasoactive drugs.Methods This comprehensive systematic review examines the evidence for vasoactive drugs in the management of PH-ILD.Results A total of 1442 pubblications were screened, 11 RCTs were considered for quantitative synthesis. Unfortunately, the salient studies are limited by population heterogeneity, short-term follow-up and the selection of outcomes with uncertain clinical significance.Conclusions This systematic review underscores the necessity of establishing a precision medicine-oriented strategy, directed at uncovering and addressing the intricate cellular and molecular mechanisms that underlie the pathophysiology of PH-ILD.PROSPERO registration number CRD42023457482.

引用

页数：14

共 50 条

[1] Treatable Traits in Systemic Sclerosis [J].